Matt, Author at European Medical Journal - Page 129 of 212

Adherence Rate to Inhaled Therapies and Factors Affecting Adherence in Elderly Patients with Chronic Obstructive Lung Diseases

Adherence to treatment is essential in chronic diseases, especially in chronic obstructive lung diseases (COLD). Poor adherence to the treatment regimen…

This October 2018, EMJ Supports...

This October, EMJ has proudly showcased its support for Stoptober and World Psoriasis Day.

European Medical Journal Presents: EMJ Dermatology 6.1

The publication of EMJ Dermatology 6.1 is now available, containing a full review of the 27th European Academy of Dermatology and Venereology (EADV)…

PASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough?

The main objectives of the symposium were to review recent evidence on what difference targeting Psoriasis Area Severity Index (PASI) 90 or 100 and…

Navigating the Road to Psoriasis Control in Women: Strategies to Optimise the Reproductive Journey

The importance of discussions around the management of women of childbearing age with psoriasis, an issue that has been largely neglected for many years…

Is Complete Skin Clearance in Psoriasis the Answer?

Prof Reich outlined the new understanding of psoriasis pathogenesis, with IL-23 rather than IL-12 considered the pivotal cytokine pathway. This…

IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future

This symposium took place at the 27th European Academy of Dermatology and Venereology (EADV) Congress. The session examined the latest data for…

From Evolution to Revolution: IL-23 in the Treatment of Psoriasis Patients

This symposium, which took place during the 2018 meeting of the European Academy of Dermatology and Venereology (EADV) in Paris, France, provided…

Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis

Guselkumab is a monoclonal antibody targeting IL-23 that is approved for the treatment of patients with moderate-to-severe plaque psoriasis. Two of…

Efficacy, Sustainability, and Patient-Reported Outcomes of Guselkumab to Treat Plaque Psoriasis in the Post-Approval Setting

Plaque psoriasis is an autoimmune condition characterised by the development of red, dry, scaly skin lesions that cause irritation and pain for patients…